Here is why you are not finding anything on SAE's. The reason they occured in the first trial was tied to the a dosing schedule based on traditional antibiotics. How awesome is it that the solution is to only use a single dose instead. The more one looks, the more there is to love about Brilacidin.
"All three Brilacidin treatment arms (two single-dose regimens and one three-day dose regimen) reached the primary endpoint, with the clinical success rate for each dosing regimen statistically comparable to the clinical success rate of the FDA-approved seven-day dosing regimen of daptomycin. All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator."
News 
Market Data 
Discover 
